JP2011523857A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011523857A5 JP2011523857A5 JP2011513010A JP2011513010A JP2011523857A5 JP 2011523857 A5 JP2011523857 A5 JP 2011523857A5 JP 2011513010 A JP2011513010 A JP 2011513010A JP 2011513010 A JP2011513010 A JP 2011513010A JP 2011523857 A5 JP2011523857 A5 JP 2011523857A5
- Authority
- JP
- Japan
- Prior art keywords
- component
- complex
- apoa
- polynucleotide
- gene construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000040430 polynucleotide Human genes 0.000 claims 11
- 108091033319 polynucleotide Proteins 0.000 claims 11
- 239000002157 polynucleotide Substances 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 239000013598 vector Substances 0.000 claims 9
- 108010027004 Apolipoproteins A Proteins 0.000 claims 5
- 102000018619 Apolipoproteins A Human genes 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims 3
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 2
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 2
- 208000005452 Acute intermittent porphyria Diseases 0.000 claims 1
- -1 ApoA-III Proteins 0.000 claims 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 1
- 108010087614 Apolipoprotein A-II Proteins 0.000 claims 1
- 102000009081 Apolipoprotein A-II Human genes 0.000 claims 1
- 102100037320 Apolipoprotein A-IV Human genes 0.000 claims 1
- 108010061118 Apolipoprotein A-V Proteins 0.000 claims 1
- 102000011936 Apolipoprotein A-V Human genes 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 claims 1
- 208000006154 Chronic hepatitis C Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 208000000185 Localized scleroderma Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 101000959789 Mus musculus Interferon alpha-1 Proteins 0.000 claims 1
- 101000959702 Mus musculus Interferon alpha-5 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 206010036182 Porphyria acute Diseases 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000009621 actinic keratosis Diseases 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 108010073614 apolipoprotein A-IV Proteins 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001012 protector Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 239000012646 vaccine adjuvant Substances 0.000 claims 1
- 229940124931 vaccine adjuvant Drugs 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200801796 | 2008-06-13 | ||
| ESP200801796 | 2008-06-13 | ||
| PCT/ES2009/070224 WO2009150284A2 (es) | 2008-06-13 | 2009-06-12 | Conjugados de apo-a para la administración de compuestos biológicamente activos |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014208266A Division JP2015038124A (ja) | 2008-06-13 | 2014-10-09 | 生物学的活性を有する化合物の投与のための複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011523857A JP2011523857A (ja) | 2011-08-25 |
| JP2011523857A5 true JP2011523857A5 (https=) | 2012-07-19 |
| JP5685529B2 JP5685529B2 (ja) | 2015-03-18 |
Family
ID=41338617
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513010A Expired - Fee Related JP5685529B2 (ja) | 2008-06-13 | 2009-06-12 | 生物学的活性を有する化合物の投与のための複合体 |
| JP2014208266A Pending JP2015038124A (ja) | 2008-06-13 | 2014-10-09 | 生物学的活性を有する化合物の投与のための複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014208266A Pending JP2015038124A (ja) | 2008-06-13 | 2014-10-09 | 生物学的活性を有する化合物の投与のための複合体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20110293557A1 (https=) |
| EP (1) | EP2305309A2 (https=) |
| JP (2) | JP5685529B2 (https=) |
| CN (1) | CN102123737B (https=) |
| AU (1) | AU2009256547B2 (https=) |
| BR (1) | BRPI0915093A2 (https=) |
| CA (1) | CA2727811A1 (https=) |
| MX (1) | MX2010013759A (https=) |
| RU (1) | RU2567667C2 (https=) |
| WO (1) | WO2009150284A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2347627B1 (es) * | 2009-03-06 | 2011-10-10 | Isdin, S.A. | Peptido para el tratamiento profilactico o terapeutico de tumores de la piel en estadios iniciales. |
| CN102753574B (zh) | 2009-12-11 | 2015-05-20 | 西马生物医学计划公司 | 用于免疫治疗和抗肿瘤治疗的缀合物和组合物 |
| US20120308517A1 (en) | 2010-02-09 | 2012-12-06 | Digna Biotech, S.L. | Compositions for the treatment of infectious and tumoural diseases |
| US20110305707A1 (en) * | 2010-06-15 | 2011-12-15 | The Cleveland Clinic Foundation | Compositions and methods for treating cancer |
| HUE042314T2 (hu) | 2011-02-07 | 2019-06-28 | Cerenis Therapeutics Holding Sa | Lipoprotein komplexek és azok gyártása és alkalmazásai |
| JP2014132832A (ja) * | 2011-05-10 | 2014-07-24 | Sekisui Chem Co Ltd | 医薬、機能性食品、目的蛋白質の安定化方法、融合蛋白質、核酸、並びに、組換え体 |
| EP2748191A1 (en) * | 2011-08-25 | 2014-07-02 | F.Hoffmann-La Roche Ag | Shortened tetranectin-apolipoprotein a-i fusion protein, a lipid particle containing it, and uses thereof |
| CN103073646A (zh) * | 2012-03-13 | 2013-05-01 | 华中科技大学 | 一种运载蜂毒肽的多肽、运载蜂毒肽的纳米颗粒及其应用 |
| ES2427854B1 (es) * | 2012-03-29 | 2014-09-15 | Universidad De Valladolid | Sensores de calcio y métodos para la detección de calcio libre intracelular |
| EP2735874A1 (en) | 2012-11-21 | 2014-05-28 | Fundación Para La Investigación Biomédica Del Hospital Universitario Puerta De Hierro | Methods of diagnosing and therapeutic agents for use in the treatment of prostate cancer |
| HK1220210A1 (zh) * | 2013-06-05 | 2017-04-28 | Csl Limited | 制备载脂蛋白a-i (apo a-i)的方法 |
| KR101656929B1 (ko) * | 2014-06-02 | 2016-09-13 | 씨제이제일제당 (주) | 반추동물의 메탄 생성 저감용 사료 첨가제 조성물 |
| GB201410507D0 (en) * | 2014-06-12 | 2014-07-30 | Univ Bath | Drug delivery enhancement agents |
| KR102440820B1 (ko) * | 2015-09-08 | 2022-09-05 | 테리피온, 인크. | ApoA-1 융합 폴리펩티드 및 관련 조성물 및 방법 |
| WO2018206125A1 (en) * | 2017-05-09 | 2018-11-15 | Fundacion Para La Investigacion Medica Aplicada | Human porphobilinogen deaminase derived proteins and polynucleotides and uses thereof |
| JP7791715B2 (ja) * | 2019-04-05 | 2025-12-24 | 韓國セラミック技術院 | Ｃｓｑ－タグを用いたタンパク質の発現及び精製方法 |
| CN110483648A (zh) * | 2019-08-27 | 2019-11-22 | 南京安吉生物科技有限公司 | 一种融合多肽及其应用 |
| FR3100715B1 (fr) * | 2019-09-12 | 2023-09-29 | Francais Du Sang Ets | Utilisation de HDL dans la prophylaxie de la maladie du greffon contre l’hôte |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6408586A (en) * | 1985-10-03 | 1987-04-24 | Biotechnology Research Partners Limited | Novel lipoprotein-based drug-delivery systems |
| EP0239631A4 (en) | 1985-10-04 | 1989-01-12 | Biotech Res Partners Ltd | RECOMBINANT APOLIPOPROTEINS AND METHODS. |
| US5643757A (en) | 1994-03-21 | 1997-07-01 | American Cyanamid Company | High yield production of human apolipoprotein A1 in E. coli. |
| US5766582A (en) | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
| JP2758154B2 (ja) | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
| ATE381577T1 (de) | 1996-08-23 | 2008-01-15 | Esperion Therapeutics Inc | Verfahren zur aufreinigung von apolipoprotein-a oder apolipoprotein-e aus menschlichem plasma |
| JP2000513945A (ja) | 1996-09-11 | 2000-10-24 | エスペリオン セラピューティクス インコーポレイテッド | プロセスにおける使用のためにアポリポタンパク質および組成物を精製するためのプロセス |
| US6046166A (en) * | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| ES2146552B1 (es) | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
| US6809186B1 (en) | 1999-01-22 | 2004-10-26 | Martek Biosciences Corporation | Simple method for labeled conjugate production |
| EP1276754A4 (en) * | 2000-04-14 | 2005-04-06 | Nuvelo Inc | Materials and methods relating to lipid metabolism |
| AU2008201887B2 (en) * | 2000-11-10 | 2011-06-30 | F. Hoffmann-La Roche Ltd. | Apolipoprotein analogues |
| US20030044982A1 (en) | 2001-04-25 | 2003-03-06 | Kenneth Chien | Method to treat hemophilia by hepatic gene transfer of factor VIII/IX with vesicle vector |
| US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| EP1558275A4 (en) * | 2002-10-30 | 2009-06-24 | Us Health | TARGETING OF B1 (CLA-1) BUTARY RECEPTOR FOR THE TREATMENT OF INFECTION, SEPSIS AND INFLAMMATION |
| CA2508831C (en) | 2002-12-13 | 2012-05-01 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| TWI433693B (zh) * | 2003-02-14 | 2014-04-11 | Childrens Hosp & Res Ct Oak | 親脂藥物傳送媒介物及其使用方法 |
| JP2004277355A (ja) | 2003-03-17 | 2004-10-07 | Beacle Inc | 血友病治療用薬剤及びそれを用いた血友病治療方法 |
| ES2304069B1 (es) | 2003-08-22 | 2009-08-12 | Proyecto De Biomedicina Cima, S.L. | Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1). |
| US7431915B2 (en) * | 2003-10-31 | 2008-10-07 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
| US20050255042A1 (en) | 2003-11-24 | 2005-11-17 | The Regents Of The University Of California Office Of Technology Transfer, University Of California | On-demand cleavable linkers for radioconjugates for cancer imaging and therapy |
| US8097283B2 (en) * | 2004-01-15 | 2012-01-17 | Mount Sinai School Of Medicine | Methods and compositions for imaging |
| CA2553955C (en) * | 2004-02-10 | 2012-08-28 | Zystor Therapeutics, Inc. | Acid alpha-glucosidase and fragments thereof |
| US20060051859A1 (en) * | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| CA2604032C (en) | 2005-04-06 | 2017-08-22 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| WO2007021494A2 (en) | 2005-08-12 | 2007-02-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1917278A2 (en) | 2005-08-26 | 2008-05-07 | Cerenis Therapeutics Holding SA | Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria |
| CA2607056C (en) | 2005-10-19 | 2015-11-24 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| EP1974740A4 (en) | 2005-10-24 | 2010-09-01 | Proyecto Biomedicina Cima Sl | USE OF TGF-BETA1 INHIBITORY PEPTIDES IN THE PREPARATION OF AN IMMUNE RESPONSE MODULATING AGENT |
| EP1969000A2 (en) | 2005-12-06 | 2008-09-17 | Centre National de la Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| US20090238883A1 (en) | 2006-04-28 | 2009-09-24 | Kren Betsy T | Liver-specific nanocapsules and methods of using |
| US20080206142A1 (en) * | 2006-06-16 | 2008-08-28 | Lipid Sciences, Inc. | Novel Peptides That Promote Lipid Efflux |
| EP2049560B1 (en) * | 2006-07-13 | 2013-05-15 | Novozymes Biopharma DK A/S | Process for preparing particles of proteinaceous material |
| KR100817024B1 (ko) * | 2006-11-09 | 2008-03-26 | 재단법인 목암생명공학연구소 | 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물 |
| US20090110739A1 (en) * | 2007-05-15 | 2009-04-30 | University Of North Texas Health Science Center At Forth Worth | Targeted cancer chemotherapy using synthetic nanoparticles |
| WO2009036460A2 (en) * | 2007-09-14 | 2009-03-19 | Ambrx, Inc. | Modified human apolipoprotein a-i polypeptides and their uses |
-
2009
- 2009-06-12 US US12/997,829 patent/US20110293557A1/en not_active Abandoned
- 2009-06-12 EP EP09761841A patent/EP2305309A2/en not_active Withdrawn
- 2009-06-12 WO PCT/ES2009/070224 patent/WO2009150284A2/es not_active Ceased
- 2009-06-12 JP JP2011513010A patent/JP5685529B2/ja not_active Expired - Fee Related
- 2009-06-12 CA CA2727811A patent/CA2727811A1/en not_active Abandoned
- 2009-06-12 RU RU2011100801/10A patent/RU2567667C2/ru not_active IP Right Cessation
- 2009-06-12 AU AU2009256547A patent/AU2009256547B2/en not_active Ceased
- 2009-06-12 CN CN200980131382.9A patent/CN102123737B/zh not_active Expired - Fee Related
- 2009-06-12 BR BRPI0915093A patent/BRPI0915093A2/pt not_active Application Discontinuation
- 2009-06-12 MX MX2010013759A patent/MX2010013759A/es active IP Right Grant
-
2014
- 2014-10-09 JP JP2014208266A patent/JP2015038124A/ja active Pending
-
2015
- 2015-11-20 US US14/947,164 patent/US20160074475A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011523857A5 (https=) | ||
| RU2011100801A (ru) | Конъюгаты для введения биологически активных соединений | |
| FI3642340T3 (fi) | Muunneltu l-asparaginaasi | |
| JP2020023567A5 (https=) | ||
| JP2020531032A5 (https=) | ||
| JP2010500399A5 (https=) | ||
| JP2009292810A5 (https=) | ||
| JP2013513377A5 (https=) | ||
| JP2010515686A5 (https=) | ||
| JP2008530245A5 (https=) | ||
| JP2013172743A5 (https=) | ||
| RU2012129208A (ru) | Конъюгаты и композиции для иммунотерапии и противоопухолевого лечения | |
| JP2014500868A (ja) | 癌及び慢性感染の治療のための作動薬活性を有するｉｌ−２由来のポリペプチド | |
| HRP20191852T1 (hr) | Polipeptidi | |
| JP2012500001A5 (https=) | ||
| CN102917726A (zh) | 干扰素类似物 | |
| JP2019534884A5 (https=) | ||
| JP2011518179A5 (https=) | ||
| AU2009275135A1 (en) | Angiopoietin derived peptides | |
| CA2765188A1 (en) | Novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer | |
| WO2004016643A3 (en) | Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines | |
| JP2009112314A5 (https=) | ||
| JP2016506413A5 (https=) | ||
| TW200526780A (en) | TNF antagonists and TNF inhibitors comprising the same as the active ingredient | |
| JP2018521977A5 (https=) |